We recently compiled a list of the 12 Stocks Under $10 With High Upside Potential. In this article, we are going to take a ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

Private Advisor Group LLC trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 75.4% during the 4th ...

In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against the other stocks under $10 with high upside potential. Small-cap stocks in the U.S. have ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

Get Our Latest Stock Report on ImmunityBio ImmunityBio Stock Up 0.3 % NASDAQ:IBRX opened at $3.00 on Monday. The firm has a market capitalization of $2.09 billion, a P/E ratio of -3.26 and a beta ...

SAN DIEGO — SAN DIEGO — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $59.2 million in its fourth quarter. The San Diego-based company said it had a loss of 9 cents per share. Losses, adjusted ...